The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
Author:
Marzel Alex12, Kusejko Katharina12, Weber Rainer1, Bruggmann Philip3, Rauch Andri4, Roth Jan A5, Bernasconi Enos6, Calmy Alexandra7, Cavassini Matthias8, Hoffmann Matthias9, Böni Jürg2, Yerly Sabine7, Klimkait Thomas10, Perreau Matthieu11, Günthard Huldrych F12, Kouyos Roger D12, Anagnostopoulos A, Battegay M, Bernasconi E, Böni J, Braun D L, Bucher H C, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux C A, Günthard H F, Haerry D, Hasse B, Hirsch H H, Hoffmann M, Hösli I, Huber M, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R D, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner K J, Müller N, Nicca D, Paioni P, Pantaleo G, Perreau M, Rauch A, Rudin C, Scherrer A U, Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S,
Affiliation:
1. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland 2. Institute of Medical Virology, University of Zurich, Switzerland 3. Arud Centres for Addiction Medicine Zürich, Switzerland 4. Clinic for Infectious Diseases, Bern University Hospital, Switzerland 5. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University Basel, Switzerland 6. Division of Infectious Diseases, Regional Hospital Lugano, Switzerland 7. Laboratory of Virology and Division of Infectious Diseases, Geneva University Hospital, Switzerland 8. Service of Infectious Diseases, Lausanne University Hospital, Switzerland 9. Division of Infectious Diseases, Cantonal Hospital St. Gallen, Switzerland 10. Molecular Virology, Department Biomedicine—Petersplatz, University of Basel, Switzerland 11. University of Lausanne, Switzerland
Abstract
Abstract
Background
Human immunodeficiency virus (HIV) transmission among injecting drug users (IDUs) is increasing in the United States due to the recent opioid epidemic and is the leading mode of transmission in Eastern Europe.
Methods
To evaluate the overall impact of HIV harm reduction, we combined (1) data from the Swiss HIV Cohort Study and public sources with (2) a mathematical model expressed as a system of ordinary differential equations. The model reconstructs the national epidemic from the first case in 1980 until 2015. Phylogenetic cluster analysis of HIV-1 pol sequences was used to quantify the epidemic spillover from IDUs to the general population.
Results
Overall, harm reduction prevented 15903 (range, 15359–16448) HIV infections among IDUs until the end of 2015, 5446 acquired immune deficiency syndrome (AIDS) deaths (range, 5142–5752), and a peak HIV prevalence of 50.7%. Introduction of harm reduction 2 years earlier could have halved the epidemic, preventing 3161 (range, 822–5499) HIV infections and 1468 (range, 609–2326) AIDS deaths. Suddenly discontinuing all harm reduction in 2005 would have resulted in outbreak re-emergence with 1351 (range, 779–1925) additional HIV cases. Without harm reduction, the estimated additional number of heterosexuals infected by HIV-positive IDUs is estimated to have been 2540 (range, 2453–2627), which is equivalent to the total national reported incidence among heterosexuals in the period of 2007 to 2015.
Conclusions
Our results suggest that a paramount, population-level impact occurred because of the harm reduction package, beyond factors that can be explained by a reduction in risk behavior and a decrease in the number of drug users over time.
Funder
Swiss National Science Foundation SHCS Research Foundation Yvonne Jacob Foundation Gilead, Switzerland University of Zurich’s Clinical Research Priority Program (CRPP) “Viral Infectious Diseases: Zurich Primary HIV Infection Study” SNF
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Oncology
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|